The BCR–ABL1 fusion gene is the primary pathogenic driver of chronic myeloid leukaemia (CML) and also characterizes a subset of patients with acute lymphoblastic leukaemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.